Multiple-Dose Dose-Escalation Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
-
- STATUS
- Not Recruiting
Summary
This study is being done to help answer the following research questions about the potential new drug, LY3303560, for the treatment of AD: Is LY3303560 safe and what is the best dose? Are there side effects experienced when taking LY3303560? What the body does to LY3303560?
How does LY3303560 affect certain proteins in the brain of people with AD?
Description
The purpose of this study is to evaluate the effects of repeated monthly administrations in patients with mild cognitive impairment (MCI) due to AD or mild to moderate AD over approximately 12 months.
Details
| Condition | Alzheimer's disease |
|---|---|
| Age | 50years - 100years |
| Clinical Study Identifier | TX8187 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.